We recently published a list of Traders Heavily Sold Down These 10 Stocks on Thursday. In this article, we are going to take ...

We recently published a list of 10 Best Low Priced Growth Stocks To Invest In. In this article, we are going to take a look ...

The National Institute for Health and Care Excellence has now approved capivasertib for use on the NHS - we look at who could ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

Patterson-UTI Energy, Inc.’s PTEN share price has dipped by 18.33%, which has investors questioning if this is right time to ...

A clinical trial that looked into the effects of the new pill plus fulvestrant, a hormone therapy, found that the treatment ...

UTI ENERGY, INC. (NASDAQ:PTEN) will host a conference call on Thursday, April 24, 2025, at 9:00 a.m. Central Time to discuss results for the first quarter ended March 31, 2025. Participants ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

A new study on the genetic causes of the PTEN Hamartoma Tumour Syndrome (PHTS) has found that inhibitors of the PI3ka pathway, commonly used as anticancer drugs, are also effective against this ...

In trading on Wednesday, shares of Patterson-UTI Energy Inc. (Symbol: PTEN) crossed above their 200 day moving average of $8.68, changing hands as high as $8.71 per share. Patterson-UTI Energy Inc ...

The Institute of Cancer Research, London, which helped develop the drug, welcomed the move. | ITV National News ...